RxDoctor Payments Data

Serena Mitroo, MD

Internal Medicine · Norman, OKNPI 1780880252

Payments from drug & device makers

$610in general payments, 2019–2025

Across 35 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$106
  • GSK$105
  • Boehringer Ingelheim$79
  • Sumitomo Pharma America, Inc.$51
  • Novo Nordisk$48
  • Exact Sciences$41
  • plus $181 from 8 others

What the payments were for

  • Food & beverage$610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$610 in reported general payments places this provider in the 60th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$165,740
Medicare patients
336
Services billed
2,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$105,088
MounjaroTirzepatide73$89,718
EliquisApixaban56$64,785
JardianceEmpagliflozin49$52,577
JanuviaSitagliptin Phosphate37$37,592
FarxigaDapagliflozin Propanediol25$30,124
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$28,764
MyrbetriqMirabegron18$20,336
TrulicityDulaglutide17$20,255
Breo ElliptaFluticasone/Vilanterol23$16,392
RybelsusSemaglutide12$16,207
TradjentaLinagliptin11$13,474
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,088
Atorvastatin Calcium259$3,999
Levothyroxine Sodium346$3,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$48$121,295113 claims
Lilly USA, LLCMounjaro, Trulicity$20$109,97390 claims
Boehringer IngelheimJardiance, Tradjenta$79$66,05160 claims
GSKTrelegy Ellipta, Breo Ellipta$105$45,15662 claims
AstraZenecaFarxiga$106$30,12425 claims
Astellas Pharma US IncMyrbetriq$30$20,33618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →